Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?

Lancet

Volumn 356, Issue 9245, 2000, Pages 1902-1903

  Wolk, Alicja ^a   Andersson, Swen Olof ^a   Mantzoros, Christos S ^c   Trichopoulos, Dimitrios ^b   Adami, Hans Olov ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

EID: 0034597897     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03266-9     Document Type: Article

References (5)

1. Plasma insulin-like growth factor-I and prostate cancer risk. A prospective study
2. Insulin-like growth factor 1 and prostate cancer risk a population-based, case-control study
3. Biological effects of proatate specific antigen as an insulin-like growth factor binding protein-3 protease
4. The insulin-like growth factor axis and prostate cancer. Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
5. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) proteolysis in patients with colorectal cancer. Possible association with the metastatic potential of the tumor